Therefore, for EGFR-mutated NSCLC patients with newly developed BMs, it's of great interest to know whether the time of brain RT could be delayed after TKI administration alone to avoid the serious neurological side effects. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.